ArticleFrontiers in molecular biosciences2025
Specificity of mRNA binding to proteins within the NMD machinery is influenced in cancer.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The nonsense-mediated mRNA decay (NMD) process is recognized as the quality control of mRNAs to maintain their integrity and production of functional proteins. Readthrough of aberrant mRNA containing premature termination codons (PTCs) can induce the production of truncated proteins with negative functionalities. Methods: To elucidate the structural and mechanistic basis of NMD components, we performed molecular dynamic simulations (MDS) to analyze their dynamic behavior across different stages of the process. We further investigated how cancer-associated mutations alter mRNA-binding protein (RBP) interactions within the NMD machinery. Results and Discussion: Over the simulation time, the mRNA containing PTCs underwent significant conformational rearrangements, ultimately forming stable interactions with the eukaryotic class-I release factor (eRF1). The efficiency of eRF1 in recognizing stop codons (UAG, UGA, or UAA) nitrogenous bases was identified, revealing a stronger preference toward UAA. Due to the lower structural stability, the AU-rich mRNA motifs showed a diminished eRF1 binding affinity relative to other PTC-containing transcripts. Among the studied cancer variants, the D9Y, R10S, F56V, P89L, and I62M residues were found to either enhance or disrupt eRF1-mRNA interactions. Similarly, when evaluating EIF4A3 RBP from the exon junction complex (EJC), the P114L and G309A mutations significantly impaired the protein-mRNA binding affinity. Surface residue mapping of SMG1 kinase revealed that it engages with SMG8, SMG9, and UPF1 in a sequential binding order, displaying the highest affinity for SMG8. Overall, these findings contribute to the mechanistic understanding of molecular properties for different RBPs from the NMD process, which can be the basis of developing new therapeutic strategies against genetic disease or cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.